EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neoadjuvant chemotherapy plus PD-1 blockade for locally advanced gastric cancer: Clinical outcomes and CD103+CD8+ T cells as a response-associated biomarker

Neoadjuvante Chemotherapie plus PD-1-Blockade bei lokal fortgeschrittenem Magenkrebs: klinische Ergebnisse und CD103+CD8+ T-Zellen als biomarker für das Ansprechen

Chunlin Hao, Jidong Tan, Shuai Liu, Xiaolong Zhao, Xisheng Yang, Mengbin Li, Chunsheng Xu

Frontiers in Oncology · 10.11.2026 · 16

DOI: 10.3389/fonc.2026.1948752 ↗

Auf einen Blick

In 144 Patient:innen mit lokal fortgeschrittenem Magenkrebs war neoadjuvante Chemotherapie plus PD-1-Inhibitor mit pCR- und MPR-Raten sowie hoher R0-Resektionsrate verbunden. PD-L1 CPS ≥1 war mit besserem pathologischen Ansprechen assoziiert.

Fragestellung

Welche klinischen Ergebnisse und welche Biomarker-assoziierten Merkmale des Ansprechens zeigen sich unter neoadjuvanter Chemotherapie plus PD-1-Blockade bei LAGC?

Methode

Retrospektive Kohortenstudie mit 144 Patient:innen; Therapie zwischen Juni 2021 und Dezember 2025, gefolgt von kurativer Operation. Explorative Multiplex-Immunfluoreszenz in 36 sintilimab-behandelten Patient:innen.

Ergebnisse

pCR 18,0 %, MPR 36,0 %, R0-Resektion 95,0 %. 1-Jahres-OS 86,9 %, 1-Jahres-DFS 77,4 %. Unerwünschte Ereignisse: Grad 1–2 bei 91,7 %, Grad 3 bei 30,6 %, keine Grad 4/5.

Einschränkungen

Retrospektive Kohorte; explorative Analyse nur in einem Subset von 36 Patient:innen; biomarkerbezogene Befunde prospektiv zu validieren.

Schlussfolgerung der Autor:innen

In dieser retrospektiven chirurgischen Kohorte war neoadjuvante Chemotherapie plus PD-1-Blockade mit guten pathologischen Ansprechraten, hoher R0-Resektionsrate und beherrschbarer Toxizität verbunden. Höhere PD-L1-Expression war mit pathologischem Ansprechen assoziiert, nicht mit Überleben.

Kernaussagen

  • pCR 18,0 % und MPR 36,0 % unter neoadjuvanter Therapie
  • PD-L1 CPS ≥1 mit höherer Wahrscheinlichkeit für MPR assoziiert
  • CD103+CD8+ T-Zell-Zunahme bei Responder:innen in der Explorationsanalyse

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 10.11.2026. Verfasst von Chunlin Hao und 6 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Programmed death-1 (PD-1) inhibitors combined with chemotherapy are established for advanced gastric cancer, but their role in the neoadjuvant treatment of locally advanced gastric cancer (LAGC) remains incompletely defined. Biomarkers associated with pathological response are also needed to improve patient stratification.

Methods

This retrospective cohort included 144 patients with LAGC who received neoadjuvant chemotherapy plus a PD-1 inhibitor followed by curative-intent surgery between June 2021 and December 2025. Pathological and radiographic responses, survival, surgical outcomes, and treatment-related adverse events were evaluated. Multiplex immunofluorescence was performed in paired tumor specimens from an exploratory subset of 36 sintilimab-treated patients. Multivariable logistic and Cox regression analyses were used to assess factors associated with pathological response and survival.

Results

The pathological complete response (pCR) and major pathological response (MPR) rates were 18.0% and 36.0%, respectively, and the R0 resection rate was 95.0%. The 1-year overall survival (OS) and disease-free survival (DFS) rates were 86.9% and 77.4%, respectively. Grade 1–2 treatment-related adverse events occurred in 91.7% of patients and grade 3 events in 30.6%; no grade 4 or 5 events occurred. PD-L1 CPS ≥1 was independently associated with a higher likelihood of MPR (adjusted OR for non-MPR, 0.31; 95% CI, 0.13–0.70; P = 0.006), but was not independently associated with OS or DFS. Baseline intratumoral CD103 + CD8 + T-cell density was numerically higher in responders than in non-responders, but this difference was not significant after false discovery rate correction (adjusted P = 0.0662). Paired analyses showed a greater treatment-associated increase in CD103 + CD8 + T-cell density among responders, whereas no statistically significant difference in CD103 - CD8 + T-cell density was observed between response groups.

Conclusion

In this retrospective surgical cohort, neoadjuvant chemotherapy plus PD-1 blockade was associated with encouraging pathological response rates, a high R0 resection rate, and manageable toxicity. Higher PD-L1 expression was associated with pathological response but not survival. Exploratory paired-tissue findings suggest that treatment-associated increases in intratumoral CD103 + CD8 + T-cell density may represent a response-associated immune feature requiring prospective validation.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Hao, C., Tan, J., Liu, S., Zhao, X., Yang, X., Li, M., & Xu, C. (2026). Neoadjuvant chemotherapy plus PD-1 blockade for locally advanced gastric cancer: Clinical outcomes and CD103+CD8+ T cells as a response-associated biomarker. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1948752

Vancouver

Hao C, Tan J, Liu S, Zhao X, Yang X, Li M, et al. Neoadjuvant chemotherapy plus PD-1 blockade for locally advanced gastric cancer: Clinical outcomes and CD103+CD8+ T cells as a response-associated biomarker. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1948752

BibTeX
@article{Hao2026,
  author = {Hao, Chunlin and Tan, Jidong and Liu, Shuai and Zhao, Xiaolong and Yang, Xisheng and Li, Mengbin and Xu, Chunsheng},
  title = {Neoadjuvant chemotherapy plus PD-1 blockade for locally advanced gastric cancer: Clinical outcomes and CD103+CD8+ T cells as a response-associated biomarker},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1948752}
}
Kostenlos starten →